Gilead Sciences : View Q4 & Full Year 2021 Presentation

Q4 & FY21 Financial Results

F e b r u a r y 1 , 2 0 2 2

Confidential - Internal Use Only

Forward-Looking Statements

Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilead's business, financial condition and results of operations; the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales and Gilead's ability to effectively manage the global supply and distribution of Veklury; Gilead's ability to achieve its anticipated full year 2022 financial results, including as a result of potential adverse revenue impacts from COVID-19, increases in R&D expenses and potential revenues from Veklury; Gilead's ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead's ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead's ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including those involving Arcus Biosciences, Inc. and Merck & Co., Inc.; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the risk that FDA may not remove clinical holds currently in place on any clinical trials, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Trodelvy, domvanalimab, etrumadenant, magrolimab, quemliclustat and remdesivir, and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead's product candidates or the product candidates of Gilead's strategic partners; Gilead's ability to submit new drug applications for new product candidates or expanded indications, including Trodelvy and Yescarta, in the currently anticipated timelines; Gilead's ability to receive regulatory approvals in a timely manner or at all, including approvals for Hepcludex, Tecartus, Trodelvy, Yescarta and lenacapavir, and the risk that any such approvals may be subject to significant limitations on use; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products, including Tecartus, Trodelvy and Veklury; and other risks identified from time to time in Gilead's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

2

Contents

Q421 & FY21 Key Takeaways

Commercial Highlights

CMO Updates

Financial Performance

Appendix

4-5

6-14

15-23

24-29

30-36

Gilead Q421 & FY21 Key Takeaways

Strong Financial Results

Recent Regulatory Approvals & Filings

Active Pipeline

Expansion

Continuing in 2022

• Exceeded 2021 full year revenue by 11% compared to initial guidance at the midpoint
• EPS impacted by legal settlement and Arcus opt-in expense
• Veklury continued to play key role in pandemic; 2021 full year revenue of $5.6B
• Biktarvy grew $1.4B (19% YoY) to $8.6B for FY21
• Effectively managed $1.3B Truvada and Atripla LOE impact
• Received MAA approval for Trodelvy in 2L mTNBC
• Received sBLA approval for Tecartus in aALL; submitted sBLA and MAA for Yescarta 2L LBCL
• Received expanded Veklury label in the U.S. (2022) and EU (2021)
• Submitted BLA filing for Hepcludex
• Dosed first patient in Phase 1 oral COVID nucleoside for treatment of COVID-19 in Jan 2022
• 2+ long-acting candidates moving into clinical development for HIV treatment
• Opted into 4 Arcus assets in Q421, adding 6 clinical stage programs with 3+ more planned
• Collaborations with Merck exploring Trodelvy and Keytruda combinations
• Over 20 planned initiations, including 15 Trodelvy trials, 7 of which are Phase 3

4 Note: aALL - adult acute lymphocytic leukemia. BLA - biologics license application. LBCL - large B cell lymphoma. LOE - loss of exclusivity. MAA - marketing authorization application. mTNBC - metastatic triple-negative breast cancer. sBLA - supplemental biologics license application.

2022 Focus: Select Key Catalysts Across Portfolio

1H222H22

Program	Trial	Indication	Update	Status		Program	Trial	Indication	Update	Status

	TROPiCS-02	HR+/HER2- mBC	Phase 3 topline readout
	EVOKE-02	1L NSCLC	Phase 2 FPI
Trodelvy
	ASCENT-03	1L mTNBC PD-L1-	Phase 3 FPI
	ASCENT-04	1L mTNBC PD-L1+	Phase 3 FPI
	ZUMA-7	2L LBCL	sBLA decision
Yescarta
	ZUMA-5	R/R FL	MAA decision
Lenacapavir	CAPELLA	HIV Tx in HTE	NDA decision

	TROPiCS-02	HR+/HER2- mBC	Potential sBLA/MAA
	submission
Trodelvy
	EVOKE-03	1L	NSCLC	Phase 3 FPI
Magrolimab	ENHANCE-3	1L	Unfit AML	Phase 3 FPI1
Yescarta	ZUMA-7	2L	LBCL	MAA decision
Tecartus	ZUMA-3	aALL	MAA decision
Hepcludex	MYR301	HDV	BLA decision
Domvanalimab	ARC-7	1L	NSCLC	Phase 2 PFS data
Etrumadenant	ARC-6	CRPC	Interim Phase 2 data
Quemliclustat	ARC-8	1L	PDAC	Phase 2 PFS data
				Completed	On Track

Note: aALL - adult acute lymphocytic leukemia. AML - acute myeloid leukemia. BLA - biologics license application. CRPC - castrate-resistant prostate cancer. FL - follicular lymphoma. FPI - first patient in. HDV - hepatitis D virus. HIV - human immunodeficiency virus. HR+/HER2- mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. HTE - heavily treatment-experienced. LBCL - large B cell lymphoma. MAA -

5 marketing authorization application. mTNBC - metastatic triple-negative breast cancer. NDA - new drug application. NSCLC - non-small cell lung cancer. PDAC - pancreatic ductal adenocarcinoma. PFS - progression free survival. R/R - relapsed/refractory. sBLA - supplemental biologics license application. Tx - treatment. 1 Subject to shifts in timeline pending resolution of FDA partial clinical holds.